Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 45

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 45
---
 Nasdaq Capital Market Listing” of this proxy statement/prospectus. The Company has applied for listing of the combined company’s Common Shares and traded warrants on the Nasdaq under the proposed symbols “NCEL” and “NCELW”, respectively, to be effective at the consummation of the Merger. While trading on the Nasdaq Stock Market is expected to begin following the Closing, there can be no assurance that the combined company’s securities will be listed on Nasdaq or that a viable and active trading market will develop. viii See “ Risk Factors — NLS Risk Factors — If NLS cannot satisfy, or continue to satisfy, the initial listing requirements and other rules of Nasdaq, NLS’s securities may not be listed or may be delisted, which could negatively impact the price of its securities and your ability to sell them.” Q.What listing standards will the combined company be required to meet to maintain its listing on Nasdaq? The combined company is expected to comply with Nasdaq’s continued listing standards, which include (but are not limited to) requirements regarding minimum market capitalization, shareholders’ equity, bid price, and certain corporate governance criteria. However, NLS is and shall continue to be a foreign private issuer after the Merger. As such, NLS is and will continue to be eligible for an exemption from certain Nasdaq corporate governance requirements that apply to issuers that are not foreign private issuers. Because Nasdaq’s standards are subject to periodic review and revision, NLS and Kadimastem will continuously monitor its compliance with such criteria as they evolve from time to time. Q.Will shareholders be informed whether the combined company has received Nasdaq listing approval prior to the shareholder vote on the Merger and related proposals? Yes. To the extent such approval is not obtained before this proxy statement/prospectus is finalized, NLS will furnish a Report on Form 6 -Kto disclose such approval. Q.How does the NLS Board recommend NLS shareholders vote? After careful consideration, the NLS Board recommends that NLS’s shareholders vote: •“FOR” Proposal No. 1 to approve the Merger Agreement. •“FOR” Proposal No. 2 to approve the ordinary share capital increase with contribution of the Kadimastem shares to implement the Merger. •“FOR” Proposal No. 3 to approve the ordinary share capital increase regrading the issuance of preferred shares. •“FOR” Proposal No. 4 to approve the reinstatement of the capital band. •“